FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022145061> ?p ?o ?g. }

• W2022145061 endingPage "3396" @default.
• W2022145061 startingPage "3389" @default.
• W2022145061 abstract "Lung cancer is the leading cause of cancer mortality worldwide and despite efforts made to improve clinical results, continuing poor survival rates indicate that novel therapeutic approaches are needed. Valproic acid (VPA), a short-chain branched fatty acid used mainly for the treatment of epilepsy and bipolar disorder, has been shown to inhibit class I histone deacetylases (HDAC-I), a group of enzymes involved in chromatin remodeling and which are thought to play a role in tumor development. Although evidence of VPA's therapeutic efficacy has also been observed in patients with solid tumors, the very high concentration required to induce antitumor activity limits its clinical usefulness. We used a panel of NSCLC cell lines to evaluate the activity and mechanisms of action of organosulfur valproic acid derivatives, a promising new class of compounds designed to improve the safety and efficacy of the valproic acid molecule and created by coupling it with a hydrogen sulfide (H2S)-releasing moiety. Our results highlighted the increased cytotoxic activity of the novel organosulfur derivatives, ACS33 and ACS2, with respect to VPA, starting from low concentrations. In particular, ACS2 exhibited important pro-apoptotic activity triggered by the mitochondrial pathway and also showed anti-invasion potential. Furthermore, our in vitro results identified a highly effective combination schedule of ACS2 and cisplatin capable of inducing a synergistic interaction even when the two drugs were used at low concentrations, which could prove a valid alternative to traditional chemotherapeutic regimens used for advanced lung cancer. Further studies are needed to confirm these preliminary findings. J. Cell. Physiol. 227: 3389–3396, 2012. © 2011 Wiley Periodicals, Inc." @default.
• W2022145061 created "2016-06-24" @default.
• W2022145061 creator A5023676582 @default.
• W2022145061 creator A5024845131 @default.
• W2022145061 creator A5031940866 @default.
• W2022145061 creator A5035580064 @default.
• W2022145061 creator A5047952050 @default.
• W2022145061 creator A5048641218 @default.
• W2022145061 creator A5058164461 @default.
• W2022145061 creator A5059309705 @default.
• W2022145061 creator A5061756597 @default.
• W2022145061 creator A5065375189 @default.
• W2022145061 creator A5069404153 @default.
• W2022145061 creator A5075055655 @default.
• W2022145061 date "2012-06-21" @default.
• W2022145061 modified "2023-10-17" @default.
• W2022145061 title "Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity" @default.
• W2022145061 cites W1596495551 @default.
• W2022145061 cites W1980456955 @default.
• W2022145061 cites W1984025642 @default.
• W2022145061 cites W1987031003 @default.
• W2022145061 cites W1987271093 @default.
• W2022145061 cites W1989696433 @default.
• W2022145061 cites W1991612814 @default.
• W2022145061 cites W1994172060 @default.
• W2022145061 cites W2001555736 @default.
• W2022145061 cites W2002236775 @default.
• W2022145061 cites W2004051773 @default.
• W2022145061 cites W2008121938 @default.
• W2022145061 cites W2011396160 @default.
• W2022145061 cites W2013194099 @default.
• W2022145061 cites W2015288550 @default.
• W2022145061 cites W2018652769 @default.
• W2022145061 cites W2020599071 @default.
• W2022145061 cites W2020830322 @default.
• W2022145061 cites W2029148944 @default.
• W2022145061 cites W2029868343 @default.
• W2022145061 cites W2032919244 @default.
• W2022145061 cites W2036986058 @default.
• W2022145061 cites W2043033879 @default.
• W2022145061 cites W2043103956 @default.
• W2022145061 cites W2047571043 @default.
• W2022145061 cites W2053736534 @default.
• W2022145061 cites W2054727063 @default.
• W2022145061 cites W2055063241 @default.
• W2022145061 cites W2057829311 @default.
• W2022145061 cites W2063685408 @default.
• W2022145061 cites W2064310618 @default.
• W2022145061 cites W2065216115 @default.
• W2022145061 cites W2073109135 @default.
• W2022145061 cites W2079101776 @default.
• W2022145061 cites W2089597449 @default.
• W2022145061 cites W2099803844 @default.
• W2022145061 cites W2104885432 @default.
• W2022145061 cites W2109689528 @default.
• W2022145061 cites W2117691193 @default.
• W2022145061 cites W2126743840 @default.
• W2022145061 cites W2143658931 @default.
• W2022145061 cites W2152392221 @default.
• W2022145061 cites W2158178080 @default.
• W2022145061 cites W2165269480 @default.
• W2022145061 cites W2174598926 @default.
• W2022145061 cites W2312461597 @default.
• W2022145061 cites W2916770920 @default.
• W2022145061 cites W4211075966 @default.
• W2022145061 cites W4245042014 @default.
• W2022145061 doi "https://doi.org/10.1002/jcp.24039" @default.
• W2022145061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22212895" @default.
• W2022145061 hasPublicationYear "2012" @default.
• W2022145061 type Work @default.
• W2022145061 sameAs 2022145061 @default.
• W2022145061 citedByCount "24" @default.
• W2022145061 countsByYear W20221450612012 @default.
• W2022145061 countsByYear W20221450612013 @default.
• W2022145061 countsByYear W20221450612014 @default.
• W2022145061 countsByYear W20221450612015 @default.
• W2022145061 countsByYear W20221450612016 @default.
• W2022145061 countsByYear W20221450612017 @default.
• W2022145061 countsByYear W20221450612018 @default.
• W2022145061 countsByYear W20221450612020 @default.
• W2022145061 countsByYear W20221450612022 @default.
• W2022145061 crossrefType "journal-article" @default.
• W2022145061 hasAuthorship W2022145061A5023676582 @default.
• W2022145061 hasAuthorship W2022145061A5024845131 @default.
• W2022145061 hasAuthorship W2022145061A5031940866 @default.
• W2022145061 hasAuthorship W2022145061A5035580064 @default.
• W2022145061 hasAuthorship W2022145061A5047952050 @default.
• W2022145061 hasAuthorship W2022145061A5048641218 @default.
• W2022145061 hasAuthorship W2022145061A5058164461 @default.
• W2022145061 hasAuthorship W2022145061A5059309705 @default.
• W2022145061 hasAuthorship W2022145061A5061756597 @default.
• W2022145061 hasAuthorship W2022145061A5065375189 @default.
• W2022145061 hasAuthorship W2022145061A5069404153 @default.
• W2022145061 hasAuthorship W2022145061A5075055655 @default.
• W2022145061 hasConcept C109316439 @default.
• W2022145061 hasConcept C118552586 @default.
• W2022145061 hasConcept C126322002 @default.
• W2022145061 hasConcept C178790620 @default.

• next